Paris, February 3, 2022. Sanofi today unveiled a new bold and unifying corporate brand that supports the modernization and transformation the company launched in December 2019.Continue reading
Category Archives: AZBio News
Perkins Coie Office Hours for AZBio
Perkins Coie attorneys are available to answer questions or discuss legal challenges pertaining to intellectual property and corporate issues that may arise for AZBio Members during “AZBio Office Hours”
PathogenDx Announces the CE Marking of Its Next-Generation COVID-19 Testing Technology for the Simultaneous Detection of SARS-CoV-2 (COVID-19) and Its Variants
The Technology Provides Medical Laboratories with a Rapid (6 hours), Affordable and Accurate Test for the Detection of SARS-CoV-2 (“COVID-19”) and its Variants (“VOC”) and (“VOI”) without Sequencing.
President Biden Reignites Cancer Moonshot to End Cancer as We Know It
Biden-Harris Administration Sets Goal of Reducing Cancer Death Rate by at least 50 Percent Over the Next 25 Years, and Improving the Experience of Living with and Surviving Cancer
Aqualung Therapeutic’s ALT-100 Antibody Significantly Reduces ARDS Severity in Both Rat and Porcine (Large Animal) Preclinical Models
TUCSON, AZ / ACCESSWIRE / February 1, 2022 / Aqualung Therapeutics, an early-stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for unchecked inflammation, a characteristic of serious acute diseases; has published a study in Scientific Reports (Tadeo Bermudez lead author) highlighting the effectiveness of the eNAMPT-neutralizing ALT-100 monoclonal antibody (mAb)in reducing Acute Respiratory Distress Syndrome (ARDS)/Ventilator Induced Lung Injury (VILI) symptoms in both rat and porcine animal models.
Continue reading
C-Path and the European Joint Programme on Rare Diseases to Expand Global Impact and Partnership
PARIS, France and TUCSON, Ariz., U.S., February 1, 2022 — Critical Path Institute (C-Path), an independent global nonprofit organization, and the European Joint Programme on Rare Diseases (EJP RD), an initiative that has received funding from the European Union’s Horizon 2020 research and innovation programme, have announced a collaboration to advance technologies and methodologies that are fit for regulatory purposes to further global rare disease research and drug development.Continue reading
AZBio Welcomes New Board Members in 2022
The Arizona Bioindustry Association Board of Directors elected five new directors to its leadership team at its January 2022 meeting. The AZBio Board directs the organization’s key actions and strategies as it pursues its vision of making Arizona a Top-Ten Bioscience State.
Preclinical studies show Aqualung Therapeutic’s eNAMPT- targeting ALT-100 mAb to reduce severity of aggressive prostate cancer
Preclinical prostate cancer (PCa] studies published in the December 17th, 2021 issue of Pharmaceuticals show Aqualung Therapeutic’s ALT-100 mAb to significantly improve overall survival and to reduce distal metastases in SCID mice implanted with human prostate cancer (PCa] cells. Aqualung Therapeutics is an early stage immunotherapeutics company with an anti-inflammatory therapeutic platform to address life-threatening unchecked inflammation.
Medtronic announces FDA approval of spinal cord stimulation therapy for treating chronic pain resulting from diabetic peripheral neuropathy
Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management aloneContinue reading
Arizona State University Biodesign Institute receives three new grants totaling $5.2 million to advance the fight against Parkinson’s disease
The Michael J. Fox Foundation has awarded three new grants totaling $5.2 million to Arizona State University (ASU) to explore three pioneering treatments for Parkinson’s disease (PD).
The awards will fund research led by Principal Investigator Dr. Jeffrey H. Kordower, each targeting underlying causes of the disease, which currently affects nearly 1 million people in the U.S. alone.
The new projects focus on two primary hallmarks of PD: the loss of dopamine-producing neurons in the brain and the accumulation within nerve cells of a misfolded form of the protein alpha-synuclein (α-syn).